drugset / Trial / NCT01316055

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

NCT01316055

Phase 1 Completed 42 enrolled Acorda Therapeutics
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram) tablets in healthy adult volunteers and those with mild and moderate renal impairment, and examine between group comparisons.

Timeline

Start
2011-01
Primary completion
2011-08
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalfampridine Small molecule 7.5 mg